General Information of Drug (ID: DMXE5KM)

Drug Name
PMID25726713-Compound-47 Drug Info
Cross-matching ID
TTD Drug ID
DMXE5KM

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug(s) Targeting Smoothened homolog (SMO)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PF-04449913 DMSB068 Chronic myelomonocytic leukaemia 2A40 Approved [2]
Vismodegib DM5IXKQ Basal cell carcinoma 2C32 Approved [3]
LDE225 DMM9F25 Basal cell carcinoma 2C32 Phase 2 [4]
LY2940680 DMTJWIQ Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
BMS-833923 DM459Q7 Solid tumour/cancer 2A00-2F9Z Phase 1b [5]
LEQ-506 DM5INZP Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
TAK-441 DM7DFBL Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
PMID25726713-Compound-49 DM2CT4G N. A. N. A. Patented [1]
PMID25726713-Compound-51 DMF0OW4 N. A. N. A. Patented [1]
PMID25726713-Compound-48 DMSIOUA N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sirolimus DMGW1ID Advanced cancer 2A00-2F9Z Approved [8]
Temsirolimus DMS104F Renal cell carcinoma 2C90 Approved [9]
PF-04449913 DMSB068 Chronic myelomonocytic leukaemia 2A40 Approved [10]
Everolimus DM8X2EH Advanced cancer 2A00-2F9Z Approved [11]
Novolimus DM6ZPLQ Artery stenosis BD52 Approved [12]
Zotarolimus DMRMCXW Solid tumour/cancer 2A00-2F9Z Approved [13]
Ridaforolimus DMLHEU7 Sarcoma 2A60-2C35 Phase 3 [14]
AZD2014 DMOEARH Solid tumour/cancer 2A00-2F9Z Phase 2 [15]
MM-141 DM2RJ4D Pancreatic cancer 2C10 Phase 2 [16]
PQR309 DMMCYZ8 Squamous head and neck cell carcinom 2D60.0 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apremilast DMTWS9E Psoriasis vulgaris EA90 Approved [17]
LY2835219 DM93VBZ Breast cancer 2C60-2C65 Approved [2]
Palbociclib DMD7L94 Breast cancer 2C60-2C65 Approved [18]
Ribociclib Succinate DM9CIUW Breast cancer 2C60-2C65 Approved [19]
Trilaciclib DMP5A4T Small-cell lung cancer 2C25.Y Approved [20]
LEE011 DMMX75K Breast cancer 2C60-2C65 Phase 3 [21]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [22]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [23]
P-276 DMMJUHD Breast cancer 2C60-2C65 Phase 2 [24]
G1T38 DMQO2IT Breast cancer 2C60-2C65 Phase 2 [16]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apremilast DMTWS9E Psoriasis vulgaris EA90 Approved [17]
LY2835219 DM93VBZ Breast cancer 2C60-2C65 Approved [2]
Palbociclib DMD7L94 Breast cancer 2C60-2C65 Approved [18]
Ribociclib Succinate DM9CIUW Breast cancer 2C60-2C65 Approved [19]
Trilaciclib DMP5A4T Small-cell lung cancer 2C25.Y Approved [20]
LEE011 DMMX75K Breast cancer 2C60-2C65 Phase 3 [21]
G1T38 DMQO2IT Breast cancer 2C60-2C65 Phase 2 [16]
GLR2007 DM7DWLY Glioblastoma of brain 2A00.00 Phase 1/2 [25]
FCN-437 DMQ8VUW Breast cancer 2C60-2C65 Phase 1/2 [26]
NUV-422 DMQJQNT Malignant glioma 2A00.0 Phase 1/2 [27]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclin-dependent kinase 4 (CDK4) TT0PG8F CDK4_HUMAN Inhibitor [1]
Cyclin-dependent kinase 6 (CDK6) TTO0FDJ CDK6_HUMAN Inhibitor [1]
Serine/threonine-protein kinase mTOR (mTOR) TTCJG29 MTOR_HUMAN Inhibitor [1]
Smoothened homolog (SMO) TT8J1S3 SMO_HUMAN Inhibitor [1]

References

1 Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
4 Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer. 2014 Sep 9;111(6):1168-79.
5 Clinical pipeline report, company report or official report of Exelixis (2011).
6 Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. ChemMedChem. 2013 Aug;8(8):1261-5.
7 TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. Int J Cancer. 2013 Oct 15;133(8):1955-66.
8 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
9 Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9.
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
13 Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008 Jun;25(3):475-516.
14 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
15 Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12.
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
18 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
19 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
20 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
21 Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
22 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
23 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
24 Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
25 Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals.
26 Clinical pipeline report, company report or official report of Fochon Pharmaceuticals.
27 ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.